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Csf3r mutations in mice confer a strong clonal
HSC advantage via activation of Stat5
Fulu Liu,1 Ghada Kunter,1 Maxwell M. Krem,1 William C. Eades,1 Jennifer A. Cain,1
Michael H. Tomasson,1 Lothar Hennighausen,2 and Daniel C. Link1
1Department

of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, Missouri, USA.
2Laboratory of Genetics and Physiology, NIDDK, NIH, Bethesda, Maryland, USA.

A fundamental property of leukemic stem cells is clonal dominance of the bone marrow microenvironment.
Truncation mutations of CSF3R, which encodes the G-CSF receptor (G-CSFR), are implicated in leukemic progression in patients with severe congenital neutropenia. Here we show that expression of a truncated mutant
Csf3r in mice confers a strong clonal advantage at the HSC level that is dependent upon exogenous G-CSF.
G-CSF–induced proliferation, phosphorylation of Stat5, and transcription of Stat5 target genes were increased
in HSCs isolated from mice expressing the mutant Csf3r. Conversely, the proliferative advantage conferred by
the mutant Csf3r was abrogated in myeloid progenitors lacking both Stat5A and Stat5B, and HSC function
was reduced in mice expressing a truncated mutant Csf3r engineered to have impaired Stat5 activation. These
data indicate that in mice, inappropriate Stat5 activation plays a key role in establishing clonal dominance by
stem cells expressing mutant Csf3r.
Introduction
There is accumulating evidence suggesting that most leukemia
is initiated by rare cancer stem cells, referred to as leukemic stem
cells (LSCs). LSCs are functionally defined as cells able to generate leukemia upon transfer to an appropriate host (1). Two fundamental and interrelated properties of LSCs are the capacity for
self-renewal and clonal dominance. Clonal dominance refers to the
clonal expansion of LSCs within the bone marrow microenvironment at the expense of normal hematopoietic cells.
The mechanisms by which mutations and/or epigenetic
changes that accumulate during leukemogenesis contribute to
clonal dominance of LSCs are largely unknown. On a functional
level, acquisition of clonal dominance represents a competitive
advantage in the bone marrow microenvironment, as suggested
by stochastic models (2). A requisite property for clonal dominance is the ability to self-renew. The capacity for self-renewal
can be achieved either by transformation of HSCs with inherent
self-renewal capacity or by the acquisition of this ability in committed progenitor populations during leukemogenesis (3). The
molecular pathways that confer clonal dominance have been
largely unexplored, though a recent study utilizing retroviral
mutagenesis showed that the majority of retroviral integrations
associated with clonal dominance (both malignant and nonmalignant) occurred near genes involved in the regulation of HSC
self-renewal, proliferation, or apoptosis (4).
Severe congenital neutropenia (SCN) is a congenital bone marrow failure syndrome characterized by severe neutropenia present
from birth, an arrest of myeloid differentiation at the promyelocyte/myelocyte stage, and a marked propensity to develop acute
myeloid leukemia (AML) or a myelodysplastic syndrome (MDS) (5,
6). The cumulative risk of MDS/AML in patients with SCN after
Nonstandard abbreviations used: AML, acute myeloid leukemia; G-CSFR, G-CSF
receptor; KSL, c-kit+Sca+lineage–; LSC, leukemic stem cell; MDS, myelodysplastic syndrome; SCN, severe congenital neutropenia.
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10 years is 11%–21% (7, 8). Treatment with G-CSF is effective in
increasing neutrophil counts and preventing infections (9); however, the quantity and duration of G-CSF treatment are correlated
with an increased risk of MDS/AML (7, 8).
Nonsense mutations of CSF3R that truncate the distal cytoplasmic portion of the G-CSF receptor (G-CSFR) are present in
approximately 40% of patients with SCN (10). These mutations
are acquired and strongly associated with the development of
AML/MDS (10). Expression of mutant G-CSFR in myeloid cell
lines results in enhanced proliferative and survival signals (11–13).
Moreover, transgenic mice carrying truncating mutations of Csf3r
display a hyperproliferative response to G-CSF (14, 15). However,
these mice do not develop MDS/AML; thus, a causal relationship
between CSF3R mutations and leukemia has not been established.
In the present study, we investigated the mechanisms by which
cells containing mutant CSF3R gain clonal dominance in vivo.
Surprisingly, competitive repopulation studies using HSC from
targeted transgenic (knockin) mice carrying the Csf3r truncation
mutation showed no clonal advantage. However, short-term treatment with G-CSF resulted in a marked competitive advantage of
mutant HSC. We utilized this inducible model to characterize the
molecular pathways mediating HSC clonal dominance. These
studies suggest that accentuated Stat5 activation plays a key role in
establishing clonal dominance by HSC-expressing mutant Csf3R.
Results
The d715 G-CSFR confers a competitive advantage at the HSC level in a
G-CSF–dependent fashion. We previously described the generation of
mice carrying a targeted (knockin) mutation of their Csf3r gene
that is representative of the truncation mutations found in SCN
(15). Of note, the targeted transgenic (knockin) approach preserves the genomic organization of the Csf3r allele; accordingly, the
mutant G-CSFR is expressed in a development- and lineage-specific fashion. These mice, termed “d715 G-CSFR,” have normal basal
granulopoiesis but exhibit an exaggerated neutrophil response to
exogenous G-CSF. To examine the effect of the d715 G-CSFR on
HSC function, a competitive repopulation assay was performed.
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Figure 1
The d715 G-CSFR confers a competitive repopulation advantage that is dependent upon exogenous G-CSF administration. Irradiated syngeneic mice were reconstituted with a 1:1 ratio of d715 G-CSFR (Ly5.2+) and wild-type (Ly5.1+) bone marrow cells. (A) The percentage of blood
neutrophils (Gr-1), B lymphocytes (B220), T lymphocytes (CD3), and monocytes (F4/80) that were derived from d715 G-CSFR (d715) cells is
shown (n = 9). (B and C) The mice were then treated with G-CSF (10 μg/kg/d; n = 5) or saline alone (n = 4) for 21 days and the contributions of
d715 G-CSFR cells in the blood (B) and bone marrow (C) were measured. Data represent the mean ± SEM. *P < 0.05.

Recipient mice were reconstituted with a 1:1 ratio of d715 G-CSFR
and wild-type bone marrow cells, and the contribution of d715
G-CSFR cells to hematopoiesis was determined by flow cytometry. At 6 months after transplantation, the contribution of d715
G-CSFR cells to the neutrophil, B lymphocyte, T lymphocyte, and
monocyte lineages in the blood was near the predicted 50% level,
indicating that the d715 G-CSFR does not confer a competitive
advantage (Figure 1A).
In patients with SCN, the systemic level of G-CSF is high, either
because of increased endogenous production or its pharmacologic administration (16). To simulate this increase in systemic
G-CSF, we treated the chimeric mice with G-CSF (10 μg/kg/d) for
3 weeks and repeated the chimerism analysis (Figure 1, B and C).
After G-CSF treatment, nearly all of the circulating neutrophils
were derived from d715 G-CSFR cells (saline, 55.5% ± 4.4% versus
G-CSF, 97.6% ± 1.2%; P < 0.001). Likewise, nearly all (98.6% ± 0.7%)
of Gr-1+ granulocytic cells in the bone marrow were of d715
G-CSFR origin after G-CSF treatment. A significant increase in the
contribution of d715 G-CSFR cells to the B lymphocyte lineage in

the bone marrow also was observed (saline, 61.2% ± 6.4% versus
G-CSF, 89.1% ± 5.7%; P < 0.001); the lack of significant increase in
circulating B or T lymphocytes after only 3 weeks of G-CSF treatment likely reflects the long half-life of these cells.
The increase in d715 G-CSFR chimerism in the B lymphocyte
lineage raised the possibility that the d715 G-CSFR confers a
competitive advantage at the HSC level after G-CSF treatment. To
address this possibility, chimerism in c-kit+Sca+lineage– (KSL) cells,
a cell population enriched in HSCs, was assessed. In saline-treated
mice, the percentage of KSL cells derived from d715 G-CSFR cells
was 53.3% ± 11.5% (Figure 2). After 3 weeks of G-CSF treatment,
this percentage increased to 97.8% ± 0.8% (P < 0.001). We next
asked whether short-term (3-week) treatment with G-CSF results
in durable increases in d715 G-CSFR chimerism. A separate cohort
of chimeric mice was generated by transplanting equal numbers of
wild-type and d715 G-CSFR bone marrow cells into recipient mice.
Five months after transplantation, these mice were treated for
3 weeks with G-CSF or saline and then followed for an additional
3 months. As expected, immediately after G-CSF treatment, virtu-

Figure 2
The contribution of d715 G-CSFR cells to the KSL cell compartment is increased after G-CSF treatment. Chimeric mice generated as described
in Figure 1 were treated with saline or G-CSF (10 μg/kg/d) for 21 days, and the percentage of KSL cells in the bone marrow derived from d715
G-CSFR cells was determined. (A) Representative scatter plot showing the strategy to identify KSL cells (boxed); data are gated on lineage – cells
(data not shown). (B) Representative scatter plots gated on KSL cells showing the percentage of d715 G-CSFR (Ly5.2+) cells. (C) The percentage of KSL cells derived from d715 G-CSFR cells is shown (n = 4–5 each). Data represent the mean ± SEM. *P < 0.001.
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Figure 3
Long-term d715 G-CSFR chimerism following G-CSF treatment is increased. Chimeric mice generated as described in Figure 1 were treated
5 months after bone marrow transplantation (BMT) with saline alone or G-CSF (10 μg/kg/d) for 21 days (indicated by the gray box). The percentage of circulating neutrophils (A) and B lymphocytes (B) derived from d715 G-CSFR cells was determined at the indicated times (n = 6–7 for each
group). (C). Bone marrow was harvested from chimeric mice after treatment with G-CSF or saline and transplanted into secondary recipients
(n = 5–10 each cohort of recipient mice). Shown is the percentage of d715 G-CSFR cells in the blood of the secondary recipients 4 months after
transplantation. Data represent the mean ± SEM. *P < 0.001.

ally all of the circulating neutrophils were of d715 G-CSFR origin
(Figure 3A). This increase persisted 3 months after discontinuing
G-CSF treatment; the percentage of circulating neutrophils derived
from d715 G-CSFR cells was 69.2% ± 3.28% versus 47.3% ± 2.07%
for saline-treated mice (P < 0.001). Strikingly, G-CSF treatment
also significantly increased the contribution of d715 G-CSFR cells
to the B lymphocyte lineage. Three months after discontinuing
G-CSF, the percentage of circulating B lymphocytes derived from
d715 G-CSFR cells was 76.6% ± 1.98% versus 56.9% ± 2.35% for
saline-treated mice (P < 0.001).
A defining feature of HSC is their ability to support multilineage
long-term engraftment after transplantation into recipient mice.
Consequently, we transplanted bone marrow from chimeric mice
after treatment with G-CSF or saline into secondary recipient mice,
and d715 G-CSFR chimerism was assessed 4 months after transplantation. A significant increase in d715 G-CSFR contribution
to circulating neutrophils (66.9% ± 3.68% versus 32.8% ± 6.09%;
P < 0.001) and B lymphocytes (76.8% ± 3.90% versus 43.7% ± 6.36%;
P < 0.001) was detected in secondary recipients that had received
G-CSF treated bone marrow (Figure 3C). Collectively, these data
show that the d715 G-CSFR confers a strong competitive advantage to HSC in a G-CSF–dependent fashion.
G-CSF–induced proliferation is increased in d715 G-CSFR HSCs. The
clonal advantage of d715 G-CSFR HSCs suggested that proliferation, survival, and/or self-renewal were enhanced. To characterize the effect on proliferation, wild-type or d715 G-CSFR mice
were treated with a single dose of G-CSF, and 24 hours later, the
cell cycle status of KSL cells in the bone marrow was measured
(Figure 4). At baseline, a similar percentage of KSL were in the
S/G2/M phases of the cell cycle (wild type, 8.9% ± 2.0% versus d715
G-CSFR, 10.0% ± 3.0%; P = NS). After treatment with G-CSF, the
percentage of cycling KSL cells increased significantly in d715
G-CSFR mice (34.4% ± 2.4%), with a trend to increased cycling
in wild-type KSL cells (20.0% ± 3.8%). Of note, G-CSF induced a
significantly greater proliferative response in d715 G-CSFR compared with wild-type KSL cells (P < 0.05).
The KSL cell population is heterogeneous, containing both HSCs
and lineage-committed progenitors. Consequently, we repeated
these experiments using more restrictive criteria to identify HSCs.
948

Specifically, we determined the fraction of CD150+CD48–CD41–
lineage– cells that labeled with BrdU in vivo after G-CSF treatment.
A previous study showed that 1 in 2.2 of these cells has long-term
repopulating activity (17). Consistent with this study, the frequency of CD150+CD48–CD41–lineage– cells in the bone marrow
of wild-type mice was approximately 0.005% (Figure 4C). A similar
frequency was observed in d715 G-CSFR mice and did not change
with G-CSF treatment (data not shown). In wild-type mice, G-CSF
treatment had no effect on BrdU incorporation of CD150+CD48–
CD41–lineage– cells (Figure 4D). In contrast, in d715 G-CSFR mice,
G-CSF treatment significantly stimulated BrdU incorporation
in these cells (saline, 15.4% ± 7.6% versus G-CSF, 42.8% ± 12.9%;
P = 0.004). Together, these data suggest that proliferative signaling
in HSC is greatly enhanced by the d715 G-CSFR.
Short-term G-CSF treatment induces the activation of Stat3 and/or Stat5
target genes in KSL cells. To elucidate the molecular mechanisms by
which the d715 G-CSFR confers a clonal HSC advantage, RNA
expression profiling experiments were performed. Specifically,
wild-type or d715 G-CSFR mice were treated with a single dose
of G-CSF or saline, and 3 hours later KSL cells were sorted from
the bone marrow by flow cytometry. The 3-hour time point was
chosen to identify early transcriptional targets of G-CSF signaling in KSL cells. Of note, this brief exposure to G-CSF had no
discernible effect on KSL number or flow cytometry characteristics (data not shown). Data from 3 independent experiments were
pooled; genes that were consistently upregulated or downregulated by G-CSF treatment are summarized in Supplemental Tables
1 and 2 (supplemental material available online with this article;
doi:10.1172/JCI32704DS1). Two criteria were used to identify
genes differentially regulated by G-CSF in d715 G-CSFR KSL cells.
First, genes were selected in which the magnitude of the change
in mRNA expression after G-CSF treatment in d715 G-CSFR KSL
cells was at least 2.0-fold greater than that observed with wild-type
KSL cells. Second, a significant difference in the absolute gene
chip signal between G-CSF–treated wild-type and d715 G-CSFR
KSL cells was required. Based on these criteria, 14 genes were
identified (Table 1). Strikingly, there is evidence that Stat3
and/or Stat5 regulate the mRNA expression of 6 of these genes,
including Sprr2a (18), Tcrg (19, 20), Pim2 (21), Cdkn1a (22, 23),
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Figure 4
G-CSF–induced proliferation of d715 G-CSFR HSCs is increased. Wild-type or d715 G-CSFR mice were treated with saline or G-CSF (2 doses of
100 μg/kg, 12 hours apart); in some cases (C and D), mice also received BrdU (2 doses of 1 mg, 12 hours apart). (A) Representative histograms
showing Hoechst staining of KSL cells. (B). Shown is the percentage of KSL cells in the S/G2/M phases of the cell cycle (n = 3–4 per condition).
(C) Representative scatter plots showing the gating strategy and BrdU staining of CD150+CD48–CD41–lineage– cells. (D) Shown is the percentage of CD150+CD48–CD41–lineage– cells that labeled with BrdU (n = 5–6 per condition). Data represent the mean ± SEM.

Cish (24), and Socs2 (25). These data suggest the hypothesis that
accentuated activation of Stat3 and/or Stat5 mediates the HSC
clonal advantage of the d715 G-CSFR.
Stat5 but not Stat3 activation by G-CSF is accentuated in d715 G-CSFR
KSL cells. A flow cytometric assay to quantify the phosphorylation of Stat3 and Stat5 was used to assess the activation of these
proteins in KSL cells (26). We first validated the assay in primary
murine myeloid cells (Figure 5, A and B). Consistent with previous
studies utilizing gel shift assays (12, 27), Stat5 activation by the
d715 G-CSFR in primary myeloid cells was markedly enhanced
(AUC: wild type, 148 ± 28 and d715 G-CSFR, 371 ± 86; P < 0.05).
Again, consistent with previous reports (12, 27), Stat3 activation in d715 G-CSFR myeloid cells, though delayed, was comparable with wild-type cells (AUC: wild type, 2,053 ± 546 and d715
G-CSFR, 2,711 ± 815; P = NS).
Similar experiments were performed with KSL cells (Figure 5,
C and D). Compared with wild-type cells, both the magnitude
and duration of Stat5 activation by G-CSF was increased in
d715 G-CSFR cells (AUC: wild type, 203 ± 73 and d715 G-CSFR,
771 ± 187; P = 0.05). In contrast, Stat3 activation by G-CSF in
d715 G-CSFR KSL cells was significantly reduced at early time
points after G-CSF stimulation (Figure 5D), with a trend to a

decrease in overall Stat3 activation (AUC: wild type, 1,315 ± 491
and d715 G-CSFR, 1,020 ± 530; P = 0.16). These data show that
Stat5 activation by the d715 G-CSFR in KSL cells was enhanced,
whereas Stat3 activation was attenuated.
The hyperproliferative response of the d715 G-CSFR is abrogated in Stat5deficient myeloid progenitors. We next sought to assess the effect of
the loss of Stat5 on the clonal dominance conferred by the d715
G-CSFR. However, the engraftment potential of Stat5A–/– × Stat5B–/–
HSC is markedly impaired (28, 29), precluding the direct assessment of the d715 G-CSFR on HSC function in Stat5-deficient
cells. Instead, we determined whether the previously described
hyperproliferative phenotype conferred by the d715 G-CSFR on
myeloid progenitors is abrogated by Stat5 deficiency. In brief,
hematopoietic cells harvested from the fetal liver of wild-type or
Stat5A–/– × Stat5B–/– mice were transduced with retrovirus expressing wild-type or d715 G-CSFR and colony formation in response
to G-CSF measured. As reported previously, expression of the d715
G-CSFR in Stat5-sufficient cells resulted in a significant increase
in both colony number and average colony size (Figure 6, A and B).
In Stat5A–/– × Stat5B–/– cells, G-CSF–induced colony formation
was reduced, and the hyperproliferative response conferred by the
d715 G-CSFR was abrogated.
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Table 1
RNA expression profiling

Gene
Tcrg
Sprr2a
Tnfsf11
Cish
Pim2
Enah
Zfpn1a4
Socs2
Cdkn1a
Serpina3g
Bcat1
Cacnb2
Ltb4r1
Bhlhb2

Saline

WT
G-CSF

Fold change

Saline

d715 G-CSFR
G-CSF

Fold  change

RatioA

P valueB

318 ± 91
810 ± 124
435 ± 116
2,730 ± 525
1,382 ± 293
230 ± 83
167 ± 68
903 ± 62
987 ± 171
22,519 ± 5,363
137 ± 49
769 ± 769
1,025 ± 259
127 ± 52

202 ± 88
2,098 ± 903
251 ± 95
3,005 ± 110
1,981 ± 530
1,495 ± 127
181 ± 68
1,315 ± 335
1,541 ± 206
31,260 ± 4,761
572 ± 95
1,621 ± 77
730 ± 198
1,267 ± 179

0.64
2.59
0.58
1.10
1.43
6.50
10.08
1.46
1.56
1.39
4.18
2.11
0.71
9.98

266 ± 24
599 ± 122
232 ± 108
2,829 ± 801
1,040 ± 326
628 ± 203
248 ± 92
2,210 ± 868
791 ± 135
20,302 ± 5,034
75 ± 34
585 ± 277
3,231 ± 2,069
723 ± 583

2,492 ± 438
21,072 ± 6,628
1,116 ± 74
13,794 ± 556
6,337 ± 1,523
17,320 ± 2,265
1,105 ± 76
11,020 ± 1,488
4,057 ± 568
83,742 ± 13,422
883 ± 46
3,018 ± 595
276 ± 34
2,501 ± 133

9.37
35.2
4.81
4.88
60.09
27.6
4.46
4.99
5.13
4.12
11.8
5.16
0.09
3.46

14.7
13.6
8.34
4.43
4.25
4.24
4.11
3.42
3.29
2.97
2.82
2.45
0.12
0.35

<0.005
<0.05
<0.005
<0.0005
<0.05
<0.005
<0.0005
<0.005
<0.01
<0.05
<0.05
<0.05
<0.05
<0.005

The mean ± SEM raw signal of experiments performed in triplicate is shown. ARatio of the fold change after G-CSF treatment between wild-type and d715
G-CSFR cells. BComparing G-CSF–treated wild-type KSL cells with G-CSF–treated d715 G-CSFR KSL cells.

Loss of Stat3 and Stat5 activation by the d715F G-CSFR is associated with
decreased HSC function. To further test the hypothesis that Stat3
and/or Stat5 activation mediates the clonal HSC advantage of the
d715 G-CSFR, we next studied d715F G-CSFR–targeted transgenic
(knockin) mice. In the d715F G-CSFR mutant, the sole remaining
tyrosine (Y704) of d715 G-CSFR is mutated to phenylalanine. We
previously showed that Stat3 and Stat5 activation by the d715F
G-CSFR in primary murine myeloid cells is markedly impaired (27).
Similar results were obtained with KSL cells (Figure 7, A and B).
In fact, no detectable Stat5 or Stat3 activation was observed in
d715F KSL cells following G-CSF stimulation.
To determine whether the loss of Stat3 and Stat5 activation by
the d715F G-CSFR affected HSC function, we repeated the competitive repopulation assay using a 1:1 ratio of d715F G-CSFR and
wild-type bone marrow cells. Consistent with the known defect
in granulopoiesis in d715F G-CSFR mice (27), the contribution
of d715F G-CSFR cells to the neutrophil lineage was consistently
less than that observed in the B or T lymphocyte lineages (Figure 7,
C–E). Chimeric mice were treated with G-CSF for 3 weeks starting
4 months after transplantation. Despite the loss of Stat3 and Stat5
activation, a significant increase in d715F G-CSFR chimerism in
the neutrophil lineage was observed. However, this increase was
transitory, returning to control levels after stopping the G-CSF. In
fact, a gradual decrease in d715F G-CSFR contribution to neutrophils, B lymphocytes, and T lymphocytes was observed over time,
irrespective of whether G-CSF was given. These data suggest that
the d715F G-CSFR confers a competitive disadvantage to HSC.
Discussion
Truncation mutations of CSF3R are strongly and uniquely associated with the development of MDS/AML in patients with SCN.
Whereas truncation mutations of CSF3R are present in 78% of
cases of MDS/AML in patients with SCN (10), they are observed
in only 1%–2% of de novo AML cases (10, 30, 31). These mutations are acquired and achieve clonal dominance in the human
bone marrow microenvironment. In the present study, we show
that expression of a representative G-CSFR truncation mutant
confers a strong clonal advantage at the HSC level. However,
950

the clonal dominance is dependent upon exogenous G-CSF
administration; similar results were observed after treating mice
for 3 weeks with 2 different doses of G-CSF: 10 μg/kg/d and
100 μg/kg/d (data not shown). The requirement for high systemic levels of G-CSF may explain the unique association of CSF3R
mutations with SCN, since in SCN, systemic levels of G-CSF are
high due to increased endogenous production or pharmacologic
administration (16). A novel feature of this model is the inducibility of the HSC clonal dominance, providing a tool to explore
molecular mechanisms for this process.
There is increasing evidence that HSC quiescence is associated
with long-term repopulating activity. Transplantation studies of
phenotypically defined HSC fractionated based on cell cycle have
shown that the quiescent fraction has the highest repopulating
activity (32, 33). Moreover, loss-of-function mutations for Cdkn1a
(p21waf1) (34) or Pten (35, 36) that result in excessive HSC proliferation are associated with loss of long-term repopulating ability. In
contrast, in the present study, we show that mutant Csf3r confers
increased repopulating activity despite inducing greater proliferation of HSC (as defined by KSL or CD150+CD41–CD48–lineage–
cells). These observations suggest the possibility that the nature
of the proliferative signals generated by mutant Csf3r may preserve the long-term repopulating activity of HSC. In this regard,
it is interesting to note that Cdkn1a (p21waf) expression is strongly
induced by G-CSF in Csf3r mutant HSC (Table 1). As noted above,
Cdkn1a is a negative regulator of HSC proliferation and helps
maintain HSC quiescence. Thus it is possible that simultaneous
induction of proliferative signals and Cdkn1a expression may prevent the loss of long-term repopulating activity associated with
uncontrolled HSC proliferation.
There is considerable evidence linking Stat5 to the regulation
of HSC function. Stat5 is activated by several cytokine receptors
implicated in the regulation of HSC, including MPL and FLT3
(37, 38). Moreover, loss of function mutations for both Stat5A
and Stat5B lead to a profound defect in hematopoietic repopulating activity (28, 29, 39). Conversely, expression of a constitutively
active form of Stat5 in both murine and human hematopoietic
progenitors promoted the self-renewal and expansion of multi-
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of Stat5A × Stat5B doubly deficient
mice have suggested an obligatory
role for Stat5 in leukemogenesis
induced by BCR-ABL and TELJAK2 (43, 44). Moreover, a recent
study showed that RNAi-mediated
inhibition of STAT5 expression
in human leukemic progenitors
inhibited their long-term growth
in vitro (45). Our data provide further support for a key role for Stat5
in leukemogenesis. Specifically,
our data suggest that Stat5 activation may contribute to the acquisition of clonal dominance by LSCs.
However, Stat5 activation alone
does not appear to be sufficient to
induce leukemia, since we previously showed that d715 G-CSFR mice
did not develop leukemia despite
chronic (6-month) treatment with
G-CSF (15).
The Stat5 target genes that regulate HSC function and confer clonal dominance have not yet been
determined. A number of genes
have been implicated in the regulation of HSC self-renewal, includFigure 5
Stat5 but not Stat3 activation by G-CSF is enhanced in d715 G-CSFR cells. Wild-type or d715 G-CSFR ing Bmi1 (46), HoxB4 (47), Mef
bone marrow cells were treated in vitro for the indicated times with G-CSF (100 ng/ml), and the cells (48), Tie2 (49), Catnb (50), CEBPA
were then incubated with antibodies specific for phosphorylated Stat5 or Stat3. (A and B) The MFI of (51), Cdkn2c (p18INK4c) (52), Notch1,
Gr-1+ (myeloid) cells for pStat5 (A) and pStat3 (B) is shown. (C and D) The MFI of KSL cells for pStat5 Notch4 (53), Gfi1 (54, 55), and Nfya
(C) and pStat3 (D) is shown. Data represent the mean ± SEM (n = 4 per cohort). *P < 0.05 compared
(56). However, none of these genes
with wild-type cells at the same time point.
were significantly upregulated in
vivo in KSL cells after 3 hours of
G-CSF stimulation (data not
potential progenitors ex vivo (37, 40). Herein, we show that Stat5 shown). Studies are underway to see whether any of these genes
but not Stat3 phosphorylation by G-CSF is accentuated in Csf3R are activated at later time points after G-CSF stimulation. Of the
mutant KSL cells. Accordingly, several well-known Stat5 target genes differentially regulated by G-CSF in Csf3r mutant KSL cells
genes, including PIM2 and Cdkn1a, are induced to a greater degree (Table 1), several have been implicated in the regulation of HSC
by G-CSF in Csf3R mutant compared with wild-type KSL cells. function or leukemogenesis. As already discussed, Cdkn1a has been
Moreover, though the severe repopulating defect of Stat5A–/– × shown to regulate HSC self-renewal (34). Pim2 is a serine-threonine
Stat5B–/– cells precluded a direct measure of HSC activity, we show kinase that has been shown to play a pivotal role in the transmisthat the proliferative advantage of myeloid progenitors expressing sion of proliferative and survival signals by FLT3 ITD (47, 57). The
mutant (d715) Csf3R is dependent upon Stat5. Finally, to directly importance of these genes is currently being investigated through
assess the importance of Stat5 activation by G-CSF in the regula- the use of the relevant loss-of-function transgenic mice.
tion of HSC function, we characterized the long-term repopulating
The high rate of leukemic transformation in SCN, and the disactivity of HSCs expressing a mutant (d715F) Csf3R engineered to mal prognosis once MDS or AML develops, has led to considerable
have impaired Stat5 activation. In fact, the competitive repopulat- debate over the timing of allogeneic HSC transplantation (HSCT)
ing activity of d715F HSCs was reduced compared with wild-type in patients with SCN. Unfortunately, there are no randomized cliniHSCs. A caveat of this experiment is that other signaling pathways cal trials comparing HSCT with standard therapy in SCN. However,
besides Stat5 (and Stat3) may be disrupted by the d715F mutation. based on its strong association with MDS/AML, the presence of
Collectively, these data suggest that accentuated Stat5 activation CSF3R mutations has been proposed as an indication for HSCT,
by mutant Csf3r mediates the clonal HSC advantage.
even in the absence of MDS/AML (10). The present study supports
Stat5 has been implicated in leukemogenesis. Constitutive Stat5 this approach. Though none of the Csf3r mice developed MDS/
activation has been detected in approximately 25% of leukemias AML, our data showing that the mutant Csf3r confers a clonal HSC
(41), and it is specifically associated with leukemias carrying inter- advantage increases the likelihood that CSF3R mutations contribnal tandem duplications of FLT3 (FLT3 ITD) (42). Expression of ute to leukemic transformation. Alternatively, the dependence of
constitutively active Stat5 in hematopoietic cells results in a rap- the HSC clonal advantage on high systemic levels of G-CSF sugidly fatal myeloproliferative disease in mice (37, 41, 43). Studies gests that discontinuing G-CSF administration may result in the
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Figure 6
Stat5 deficiency abrogates the hyperproliferative response of the d715 G-CSFR in myeloid progenitors. E12–E15 fetal liver cells from wildtype or Stat5A–/– × Stat5B–/– (Stat5–/–) mice were transduced with retrovirus expressing neomycin phosphotransferase alone (Neo) or this
gene and either wild-type G-CSFR (WT GR) or d715 G-CSFR. Cells were cultured in 10 ng/ml of G-CSF and geneticin to select for transduced cells. Shown is the number of colonies (A) and average colony size (B) observed after 7–10 days. Similar results were observed in
cultures stimulated with 1 ng/ml of G-CSF (data not shown). No colonies formed in the absence of G-CSF (data not shown). Data represent
the mean ± SEM of 3 independent experiments.

loss (or at least stabilization) of the CSF3R mutant clone. Indeed,
there is a case report in which a patient with a CSF3R mutation and
AML had a spontaneous remission of AML after stopping G-CSF
(58). However, treatment with G-CSF is proven to improve surviv-

al in patients with SCN, and there currently is no other effective
therapy to increase neutrophil counts in patients with SCN. In the
absence of such a therapy, it may be prudent to consider allogeneic
HSCT in all patients with SCN who acquire a CSF3R mutation.

Figure 7
Competitive repopulation by HSC expressing the d715F G-CSFR is impaired. (A and B) Wild-type or d715F G-CSFR KSL cells were treated in
vitro for the indicated times with G-CSF (100 ng/ml) and then incubated with antibodies specific for pStat5 (A) or pStat3 (B). The MFI of triplicate
experiments is shown. (C–E) Irradiated syngeneic mice were reconstituted with a 1:1 ratio of d715F G-CSFR and wild-type bone marrow cells.
The resulting chimeric mice were treated 4 months after bone marrow transplantation with saline alone or G-CSF (10 μg/kg/d) for 21 days. The
percentage of circulating neutrophils (C), B lymphocytes (D), and T lymphocytes (E) derived from d715F G-CSFR cells was determined at the
indicated times (n = 3–4 for each group). Data represent the mean ± SEM. *P < 0.05 compared with saline-treated mice.
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Methods
Mice. d715 G-CSRR and d715F G-CSFR mice backcrossed 10 generations
onto a C57BL/6 background were generated as described previously (15,
27). C57BL/6 mice (B6.SJL-Ptprc*/Pep3b/BoyJ) that have the Ly5.1 gene
were obtained from The Jackson Laboratory. Stat5a+/– × Stat5b+/– mice outbred on a NIH Black Swiss × 129SvEv × C57BL/6 background were generated as previously described (59). These mice were intercrossed to generate
Stat5a–/– × Stat5b–/– fetuses. Mice were housed in a specific pathogen–free
environment. All experiments were approved by the Washington University
Animal Studies Committee.
Competitive repopulation assay. Wild-type (Ly5.1), d715, or d715F
G-CSFR (Ly5.2) bone marrow cells were harvested from strain- and sexmatched mice. A total of 5 million bone marrow cells were mixed at a
1:1 ratio and injected into the tail vein of lethally irradiated wild-type
mice (Ly5.1). Recipient mice were conditioned with 1,000 cGy from
a 137Cesium source at a rate of approximately 95 cGy/min 24 hours
prior to transplantation. Prophylactic antibiotics (trimethoprim-sulfamethoxazole; Alpharma) were given during the initial 2 weeks following
transplantation. Mice were analyzed 3–12 months after transplantation.
Where indicated, mice were treated with human recombinant G-CSF
(Amgen) in PBS with 0.1% low-endotoxin BSA at a dose of 10 μg/kg/d
for 21 days. Secondary bone marrow transplantation was performed
immediately following treatment with G-CSF or saline alone. Bone marrow cells (5 × 106) from the primary recipient mice were transplanted
into secondary recipient mice.
Flow cytometry. Bone marrow and blood leukocytes were processed for
flow cytometry as previously described (60). For chimerism analysis, cells
were incubated with FITC-conjugated Ly5.1, Cy5-PE–conjugated Ly5.2,
and one of the following PE-conjugated lineage markers: Gr-1 (myeloid),
B220 (B lymphocytes), CD3 (T lymphocytes), or F4/80 (monocytes; Caltag
Laboratories). Isotype-matched antibodies were used as negative controls.
Cells were analyzed on a 2-laser, 5-color FACScan flow cytometer (BD Biosciences and Cytek Development). Unless otherwise indicated, all antibodies were obtained from BD Biosciences.
To analyze KSL cells, lineage+ cells were first depleted. In brief, cells were
incubated with the following PE-conjugated lineage markers: CD3, B220,
Gr-1, and Ter-119. Following incubation with anti-PE colloid, lineage+ cells
were depleted using the AutoMacs system (Miltenyi Biotec). The lineagedepleted cells were then incubated with FITC-conjugated Sca-1, APC-conjugated c-kit, Cy5-PE–conjugated Ly5.2, and Cy7-APC–conjugated Ly5.1.
Cell cycle analysis of KSL cells. Following lineage depletion and incubation
with FITC-conjugated Sca1 and APC-conjugated c-kit, bone marrow cells
were incubated with 10 μg/ml Hoechst 33342 (Molecular Probes) in PBS
containing 0.2% BSA at 37°C for 60 minutes. Hoechst staining of the KSL
cells was assessed using a MoFlo high-speed cell sorter (Dako).
BrdU labeling. Mice (n = 5 per condition) were injected with BrdU (2 doses
of 1 mg given 12 hours apart; BD Biosciences) and either saline alone of
G-CSF (2 doses of 100 μg/kg given with the BrdU). Bone marrow cells
were harvested 12 hours after the final dose of BrdU and incubated with
FITC-conjugated CD48 (eBioscience) and CD41, biotinylated CD150
(clone number TC15-12F12.1; Biolegend), and the following panel of Cy5PE–conjugated lineage markers: CD3, B220, Gr-1, and Ter-119. Following
incubation with streptavidin-PE (eBioscience), cells were fixed, permeabilized, and incubated with PE-conjugated anti-BrdU antibody per the manufacturer’s recommendations (BrdU flow kit; BD Biosciences). Cells were
analyzed using a MoFlo high-speed cell sorter.
Expression profiling and data analysis. Groups of 8–10 wild-type, d715
G-CSFR, or d715F G-CSFR mice were treated with a single subcutaneous injection of G-CSF (100 μg/kg) or saline alone. Bone marrow cells were harvested
3 hours later and KSL cells sorted. RNA was prepared from 20,000–100,000

KSL cells using Trizol reagent (Invitrogen). Total cellular RNA samples of
100 ng were subjected to linear amplification, biotin labeling, fragmentation, and hybridization to Affymetrix MOE430 v2.0 GeneChip microarrays
per protocols of the Siteman Cancer Center Multiplexed Gene Analysis
Core Facility (http://pathology.wustl.edu/research/multiplexed.php).
Experiments were performed in triplicate.
Visualization and statistical analysis of data were performed using Decision Site (Spotfire). Signal values corresponding to the probesets were normalized to adjust for minor differences in hybridization intensities across
the 12 microarrays analyzed. After normalization, mean signal intensities for each probeset were calculated across the 3 experiments. Probesets
upregulated or downregulated by G-CSF compared with saline control
were selected based upon the following selection criteria: (a) present detection call in at least 2 of 3 probesets corresponding to the upregulated
condition; (b) absolute signal intensity > 500 in at least 2 of 3 probesets
corresponding to the upregulated condition; and (c) greater than 2-fold
change in mean signal intensity (hereafter referred to as fold-induction ratio)
between G-CSF and saline. In cases where multiple probesets corresponded
to the same gene, the probeset with the highest average signal intensity and
greatest number of present calls was used.
Assessment of Stat5 and Stat3 phosphorylation by flow cytometry. Bone marrow
cells were either incubated with FITC-conjugated Gr-1 or lineage depleted
and then incubated with FITC-Sca1 and APC–c-kit. Cells were then suspended in Opti-MEM (Invitrogen) with 10% FBS and stimulated with
G-CSF (100 ng/ml) for the indicated time at 37°C. As a control, duplicate samples were cultured without G-CSF. Following incubation, cells
were incubated in BD Phosphflow Lyse/fix buffer (BD Biosciences) for
10 minutes, permeabilized in 100% methanol at 4°C for 20 minutes, and
then incubated with anti-pStat5 (pY694) or anti-pStat3 (pY705) antibody
(BD Biosciences) at room temperature for 30 minutes.
Retroviral transduction of Stat5a–/– × Stat5b–/– fetal liver progenitors. Stable
clones of the ecotropic packaging cell line GP+E86 containing the retroviral viral vector pMPncrdleno alone or this vector with cDNAs for
wild-type murine G-CSFR or the d715 G-CSFR have been previously
described (61). Cultures of fetal liver cells from 12- to 15-dpc Stat5a–/– ×
Stat5b–/– fetuses were generated as previously described (62). Cells were
cultured for 24 hours in RPMI containing 10% FBS, 50 ng/ml of murine
thrombopoietin, 100 ng/ml of murine stem cell factor, 10 ng/ml of
murine interleukin-3, and 50 ng/ml of human flt3 ligand at 37°C in
5% CO2 (all cytokines were obtained from Peprotech). Cells were then
cocultured in the same media with irradiated (1,500 cGy) GP+E86 cells
for 48 hours. Viable cells (0.5–1 × 105 cells) recovered from these cultures were plated in MethoCult M3231 (Stem Cell Technologies) supplemented with 1 or 10 ng/ml of human G-CSF and 1 mg/ml of geneticin
(Invitrogen). Colonies containing at least 50 cells were scored on days
7–10 of culture. To determine transduction efficiency, 1–2 × 104 cultured fetal liver cells were placed in MethoCult M3434 with or without
1 mg/ml of geneticin and the percentage of colonies that were resistant to
geneticin measured. A similar transduction efficiency (range 30%–52%)
for all 3 retroviruses with both wild-type and Sta5a–/– × Stat5b–/– cells was
observed (data not shown).
Statistics. Statistical significance was determined either by a 2-way ANOVA
analysis or by a 2-sided Student t test. All data represent the mean ± SEM,
unless otherwise stated.
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